Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Two Sigma Investments LP acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 650,351 shares of the company’s stock, valued at approximately $2,075,000. Two Sigma Investments LP owned 0.96% of Perspective Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CATX. SG Americas Securities LLC raised its position in shares of Perspective Therapeutics by 41.3% during the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock valued at $83,000 after purchasing an additional 7,627 shares during the period. Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics during the fourth quarter valued at $51,000. Rhumbline Advisers grew its stake in Perspective Therapeutics by 4.5% during the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock valued at $303,000 after acquiring an additional 4,075 shares in the last quarter. WealthPlan Investment Management LLC grew its stake in Perspective Therapeutics by 18.2% during the fourth quarter. WealthPlan Investment Management LLC now owns 401,049 shares of the company’s stock valued at $1,279,000 after acquiring an additional 61,757 shares in the last quarter. Finally, Nicholson Wealth Management Group LLC grew its stake in Perspective Therapeutics by 0.4% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after acquiring an additional 7,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CATX has been the subject of several research analyst reports. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial cut their target price on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Finally, Royal Bank of Canada cut their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.50.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $2.57 on Monday. The firm has a 50-day moving average price of $2.25 and a 200-day moving average price of $2.98. Perspective Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $16.55.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now owns 59,383 shares of the company’s stock, valued at $133,017.92. The trade was a 58.96% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Juan Graham bought 33,333 shares of the stock in a transaction dated Friday, March 28th. The stock was purchased at an average price of $2.25 per share, with a total value of $74,999.25. Following the acquisition, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. The trade was a 1,649.33% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 115,696 shares of company stock worth $256,344. 3.72% of the stock is currently owned by insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.